TTrialPathMatch Me to Trials
← Back to trials
RecruitingAdvanced Solid Tumor

Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors

Eligible age

18+ yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability when given as a single medication and as a combined medication in adults with solid tumors, where the participants show a specific gene alteration in the tumor. The gene helps produce methylthioadenosine phosphorylase (MTAP) enzyme. MTAP enzyme helps in normal growth of cells. The primary objectives of the study are to assess the safety and tolerability of GS-5319 as monotherapy and combination therapy in participants with MTAP-deleted advanced solid tumors and identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the recommended dose(s) for expansion (RDE).

Sponsor: Gilead Sciences

Where it's recruiting

New Jersey

New Brunswick

Texas

San Antonio

Virginia

Fairfax

Source: ClinicalTrials.gov · NCT07128303 · last updated 2026-10-23

Study of GS-5319 Given Alone or in Combination in Adults With Solid Tu · TrialPath